A Phase I Study of Epidermal Growth Factor Receptor (EGFR) Targeted, Paclitaxel Loaded EnGeneIC Delivery Vehicles (ErbituxEDVsPac) on Immune and Tumour Responses in Patients with Advanced Epithelial Malignancies.
Phase of Trial: Phase I
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Paclitaxel (Primary)
- Indications Cancer
- Focus Adverse reactions; First in man
- 24 Jun 2014 Results were published in an EnGeneIC media release.
- 08 Oct 2012 Status changed from not yet recruiting to completed as reported by Australian New Zealand Clinical Trials Registry.
- 18 Aug 2009 New trial record